Cargando…

Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases

Recently, there has been a growing interest in the medical applications of Cannabis plants. They owe their unique properties to a group of secondary metabolites known as phytocannabinoids, which are specific for this genus. Phytocannabinoids, and cannabinoids generally, can interact with cannabinoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Śledziński, Paweł, Nowak-Terpiłowska, Agnieszka, Zeyland, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795897/
https://www.ncbi.nlm.nih.gov/pubmed/33383838
http://dx.doi.org/10.3390/ijms22010263
_version_ 1783634553041059840
author Śledziński, Paweł
Nowak-Terpiłowska, Agnieszka
Zeyland, Joanna
author_facet Śledziński, Paweł
Nowak-Terpiłowska, Agnieszka
Zeyland, Joanna
author_sort Śledziński, Paweł
collection PubMed
description Recently, there has been a growing interest in the medical applications of Cannabis plants. They owe their unique properties to a group of secondary metabolites known as phytocannabinoids, which are specific for this genus. Phytocannabinoids, and cannabinoids generally, can interact with cannabinoid receptors being part of the endocannabinoid system present in animals. Over the years a growing body of scientific evidence has been gathered, suggesting that these compounds have therapeutic potential. In this article, we review the classification of cannabinoids, the molecular mechanisms of their interaction with animal cells as well as their potential application in the treatment of human diseases. Specifically, we focus on the research concerning the anticancer potential of cannabinoids in preclinical studies, their possible use in cancer treatment and palliative medicine, as well as their influence on the immune system. We also discuss their potential as therapeutic agents in infectious, autoimmune, and gastrointestinal inflammatory diseases. We postulate that the currently ongoing and future clinical trials should be accompanied by research focused on the cellular and molecular response to cannabinoids and Cannabis extracts, which will ultimately allow us to fully understand the mechanism, potency, and safety profile of cannabinoids as single agents and as complementary drugs.
format Online
Article
Text
id pubmed-7795897
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77958972021-01-10 Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases Śledziński, Paweł Nowak-Terpiłowska, Agnieszka Zeyland, Joanna Int J Mol Sci Review Recently, there has been a growing interest in the medical applications of Cannabis plants. They owe their unique properties to a group of secondary metabolites known as phytocannabinoids, which are specific for this genus. Phytocannabinoids, and cannabinoids generally, can interact with cannabinoid receptors being part of the endocannabinoid system present in animals. Over the years a growing body of scientific evidence has been gathered, suggesting that these compounds have therapeutic potential. In this article, we review the classification of cannabinoids, the molecular mechanisms of their interaction with animal cells as well as their potential application in the treatment of human diseases. Specifically, we focus on the research concerning the anticancer potential of cannabinoids in preclinical studies, their possible use in cancer treatment and palliative medicine, as well as their influence on the immune system. We also discuss their potential as therapeutic agents in infectious, autoimmune, and gastrointestinal inflammatory diseases. We postulate that the currently ongoing and future clinical trials should be accompanied by research focused on the cellular and molecular response to cannabinoids and Cannabis extracts, which will ultimately allow us to fully understand the mechanism, potency, and safety profile of cannabinoids as single agents and as complementary drugs. MDPI 2020-12-29 /pmc/articles/PMC7795897/ /pubmed/33383838 http://dx.doi.org/10.3390/ijms22010263 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Śledziński, Paweł
Nowak-Terpiłowska, Agnieszka
Zeyland, Joanna
Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
title Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
title_full Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
title_fullStr Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
title_full_unstemmed Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
title_short Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
title_sort cannabinoids in medicine: cancer, immunity, and microbial diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795897/
https://www.ncbi.nlm.nih.gov/pubmed/33383838
http://dx.doi.org/10.3390/ijms22010263
work_keys_str_mv AT sledzinskipaweł cannabinoidsinmedicinecancerimmunityandmicrobialdiseases
AT nowakterpiłowskaagnieszka cannabinoidsinmedicinecancerimmunityandmicrobialdiseases
AT zeylandjoanna cannabinoidsinmedicinecancerimmunityandmicrobialdiseases